Life Science Consulting
Drug development costs $2.6 billion per approval and 90% of clinical candidates fail. We help pharma, biotech, and medtech organizations harness AI, data, and strategic expertise to beat those odds and get treatments to patients faster.
90%
of drugs entering clinical trials fail
25–50%
R&D cost reduction with AI-driven discovery
80–90%
Phase I success rate for AI-assisted drugs
The Problem
The economics of drug development are brutal. But AI and data-driven approaches are changing the math. Here's where the industry stands:
$2.6B
average cost to bring one drug to market
90%
clinical trial failure rate
10–15yr
average drug development timeline
$350M
average cost of a single Phase III trial
65%+
of top pharma invest in early regulatory strategy
75%
of pharma companies prioritize GenAI investments
Our Services
Six core capabilities spanning the full life science value chain — from discovery and clinical development to commercial launch and manufacturing.
R&D portfolio strategy, target prioritization, go/no-go decision frameworks, and development planning. 90% of drug candidates fail — strategic discipline at every stage gate is the single biggest lever for value creation and capital efficiency.
Protocol design, adaptive trial architectures, site selection, patient recruitment strategy, and AI-powered trial analytics. Phase III trials average $350M over 6–7 years. AI-optimized trial design has demonstrated timeline reductions of up to 80% in select programs.
Global regulatory strategy for FDA, EMA, PMDA, and NMPA. IND/NDA/BLA submissions, GxP compliance, and post-market surveillance. 65%+ of top pharma companies invest in early regulatory strategy because it prevents costly late-stage delays.
Pricing strategy, health economics and outcomes research (HEOR), payer engagement, and reimbursement pathway design. This is the largest life science consulting segment — because articulating value to payers is critical to commercial success and patient access.
75% of pharma companies prioritize GenAI investments. We deploy AI across the value chain — from target identification and molecular design to clinical trial analytics, real-world evidence, and commercial operations. We build the data infrastructure that makes AI actually work.
Production optimization, serialization and track-and-trace, biologics cold chain management, and GMP compliance. AI predictive maintenance cuts downtime by 30–50%. Digital twins simulate process changes without disrupting validated production environments.
Our Process
A 4-phase approach built for regulated environments — rigorous, milestone-driven, and always aligned to your clinical and commercial timeline.
We assess your pipeline, data landscape, regulatory posture, and organizational readiness. You get a maturity scorecard, gap analysis, and a prioritized list of high-impact interventions tied to your development timeline.
We build a phased roadmap — aligning regulatory milestones, technology investments, and organizational changes. Every recommendation ties to a clinical or commercial outcome, not just a deliverable.
We work alongside your teams — deploying AI platforms, optimizing trial designs, preparing regulatory submissions, and building the data infrastructure that accelerates every downstream decision.
We track outcomes against clinical milestones, regulatory timelines, and cost targets. We optimize models, retrain AI systems, and continuously refine strategy as your pipeline evolves.
Who We Serve
Deep domain expertise across the life science ecosystem — from pre-revenue biotechs to global pharma enterprises.
R&D transformation, portfolio optimization, AI-driven drug discovery, global regulatory strategy, and commercial launch excellence.
Pre-IND strategy, clinical trial design, investor-ready regulatory narratives, and scaled operations for companies transitioning from discovery to clinical stage.
FDA 510(k) and PMA submissions, design controls, post-market surveillance, UDI compliance, and digital health device strategy.
Autologous and allogeneic manufacturing strategy, vein-to-vein supply chain design, regulatory pathway for ATMPs, and CMO/CDMO selection.
CRO/CDMO operational efficiency, capacity planning, tech transfer optimization, and client-facing digital platforms.
SaMD regulatory strategy, clinical validation, EHR/FHIR integration, AI/ML model validation, and go-to-market for digital therapeutics.
Whether you're a startup navigating your first IND filing, a biotech scaling commercial operations, or a global pharma company transforming R&D with AI — we help you move faster, smarter, and more efficiently.
No commitment required. We'll assess your pipeline, data infrastructure, and regulatory posture — and give you an honest roadmap.